T1	Participants 80 112	patients with cardiac syndrome-X
T2	Participants 387 425	patients with cardiac syndrome-X (CSX)
T3	Participants 501 576	Thirty patients, 17 female and 13 male, with CSX were enrolled in the study
T4	Participants 900 990	No patient presented additional risk factors for increased reactive oxygen species levels.
T6	Participants 999 1192	Compared with sixteen control participants, patients with CSX had significantly higher activity of MPO and levels of MDA, but significantly lower SOD activity and levels of NOx before treatment
